News

Pharma’s Almanac || What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”

whitepages icon x

Clinical Laboratory | Paradigm4 unveils analytical development data management tool to unlock Allotrope data format (ADF) ‘treasure trove’

Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…

whitepages icon x

R&D World | The need for next generation analytics to extract valuable insights from genomic biobank data

Precision medicine is poised to transform healthcare, with biobanks being identified as a key enabler to bring it to fruition by 2030 by putting new, extended datasets at the disposal of pharmaceutical researchers and healthcare professionals. — by Marilyn Matz

whitepages icon x

European Pharmaceutical manufacturer || Paradigm4 and Alnylam partnership to accelerate RNAi- based drug discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the pace and productivity of Alnylam’s RNAi therapeutics pipeline.